Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Roslin Cells & Lonza Take On Stem Cell Media
Ultimate Goal of Initiatives Is to Facilitate Translation of Innovation into Regenerative Therapies
- Earlier this year Roslin Cells and Lonza signed a stem cell media development deal the firms hope will play a key role in the drive to translate scientific innovation in the stem cells field into clinically applied regenerative therapies. The agreement is centered on the development of clinical-grade ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.